Novelix Pharmaceuticals Limited, a active public limited company, was established on 13 December 1994 in Himayathnagar, Telangana, India. Engaging in pharmaceutical retailers & distributors within the financial and insurance service sector, it holds CIN: L67120TG1994PLC018956. Registered under ROC Roc Hyderabad. it is listed on BSE: 536565. It has an authorized capital of ₹30.00 Cr and a paid-up capital of ₹16.14 Cr.
Formerly known as Trimurthi Drugs & Pharmaceuticals Limited, Trimurthi Limited. It upholds a compliant status. In 2023, it reported revenue of ₹1.92 Cr and a net worth of ₹7.20 Cr. Its leadership includes Jivamohan Divakar Valluri (Director), Janardhan Das Kabra (Director), Venkateshwarlu Pulluru (Whole-Time Director). Past directors included Sowjanya Sarapu, Vijaykumar Taori, Jivamohan Divakar Valluri. It holds ₹8.50 M open charges and no settled loans. Its latest AGM occurred on 27 September 2024, with the balance sheet filed on 31 March 2024. It is based at Flat # 610, 6Th Floor, H.No.3-6-237/610, Lingapur La Builders ( Also Known As Amrutha Estate), Himayathnagar, Telangana, 500029.
L67120TG1994PLC018956
018956
13 December 1994
₹30.00 Cr
₹16.14 Cr
Roc Hyderabad
Listed (BSE: 536565)
Active
Explore comprehensive insights into Novelix Pharmaceuticals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Jivamohan Divakar Valluri | Director | 12 Apr 2025 | Current |
| Janardhan Das Kabra | Director | 02 Sep 2024 | Current |
| Venkateshwarlu Pulluru | Whole-Time Director | 02 Sep 2024 | Current |
| Lakshman Samala | Director | 12 Feb 2025 | Current |
| Mayuri Baidya | Additional Director | 14 Aug 2025 | Current |
| Gnana Prakash Gattu | Additional Director | 14 Aug 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 12 Feb 2022 | Past |
| Pramod Abcsdd | Director | 28 Sep 2013 | Past |
| Pramod Abcsdd | Additional Director | 08 May 2025 | Past |
| Pramod Abcsdd | Additional Director | 26 Sep 2024 | Past |
| Pramod Abcsdd | Additional Director | 19 Aug 2022 | Past |
| Pramod Abcsdd | Director | 05 Nov 2016 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Novelix Pharmaceuticals Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 37.67% increase. The company also saw a substantial improvement in profitability, with a 96.16% increase in profit. The company's net worth dipped by a decrease of 0.66%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Novelix Pharmaceuticals had a promoter holding of 66.92% and a public holding of 33.08%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹8,500,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Nov 2025 | Canara Bank | ₹8.50 M | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Novelix Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Novelix Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novelix Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on A charge with Canara Bank amounted to Rs. 0.85 Cr with Charge ID 101192851 was registered on 07 Nov 2025. was documented.
Progress on Sridevi Belide was appointed as a Additional Director was appointed as a Additional Director on 23 Oct 2025 & has been associated with this company since 2 months 22 days . was documented.
Progress on Mayuri Baidya was appointed as a Additional Director was appointed as a Additional Director on 14 Aug 2025 & has been associated with this company since 5 months . was documented.
Progress on Gnana Prakash Gattu was appointed as a Additional Director was appointed as a Additional Director on 14 Aug 2025 & has been associated with this company since 5 months . was documented.
The activity Jivamohan Divakar Valluri was appointed as a Director was appointed as a Director on 12 Apr 2025 & has been associated with this company since 9 months 2 days . was completed.
Bhoomika Choudhary was appointed as a Cfo was appointed as a Cfo on 22 Feb 2025 & has been associated with this company since 10 months 20 days . was recorded as a recent event.
The CIN of Novelix Pharmaceuticals Limited is L67120TG1994PLC018956.
Novelix Pharmaceuticals Limited is headquartered at Flat # 610, 6Th Floor, H.No.3-6-237/610, Lingapur La Builders ( Also Known As Amrutha Estate), Himayathnagar, Telangana, 500029.
Novelix Pharmaceuticals Limited was incorporated on 13 December 1994.
The current directors of Novelix Pharmaceuticals Limited are
The primary industry of Novelix Pharmaceuticals Limited is Financial And Insurance Service.
Novelix Pharmaceuticals Limited is listed. It is listed on BSE: 536565.
The authorized capital of Novelix Pharmaceuticals Limited is ₹30.00 Cr, and the paid-up capital is ₹16.14 Cr.
The compliance status of Novelix Pharmaceuticals Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX